Related Experiment Video
Updated: May 6, 2026
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Association between dementia and left atrial appendage occlusion in patients with atrial fibrillation: A
Kuan-Hsien Lu1, Cheng-Yang Hsieh2, Daniel Hsiang-Te Tsai3,4
1Department of Neurology, Chi Mei Medical Center, Tainan, Taiwan.
Insights
Left atrial appendage occlusion (LAAO) may reduce dementia risk in atrial fibrillation (AF) patients compared to direct oral anticoagulants (DOACs). This study found LAAO associated with lower dementia incidence over three years.
Area of Science:
- Cardiology
- Neurology
Background:
- Atrial fibrillation (AF) increases stroke and dementia risk.
- Observational data suggests Left Atrial Appendage Occlusion (LAAO) may mitigate dementia risk in AF patients.
Purpose of the Study:
- To compare the efficacy of LAAO versus direct oral anticoagulants (DOACs) in reducing dementia risk among AF patients.
Main Methods:
- Target trial emulation using TriNetX network data.
- Two balanced cohorts (2270 patients each) received either LAAO or DOACs.
- Propensity score matching and 3-year follow-up for primary endpoints (composite dementia, vascular dementia, Alzheimer's disease) and secondary outcomes.
Main Results:
- LAAO group showed a significantly lower risk of composite dementia at 3 years (HR 0.57; 95% CI 0.38-0.85).
- Consistent benefits observed across subgroups.
- No significant differences in secondary outcomes like mortality or stroke.
Conclusions:
- Real-world evidence suggests LAAO is linked to reduced dementia risk in AF patients compared to DOACs.
- Further prospective studies with long-term follow-up are warranted to confirm these findings.
Background:
Atrial fibrillation (AF) is a common cardiac arrhythmia linked to an elevated risk of stroke and dementia. Emerging observational evidence suggests that left atrial appendage occlusion (LAAO) may reduce the risk of dementia in patients with AF; however, further research is required to confirm this potential benefit.
Objective:
This study aimed to compare the effectiveness of LAAO vs direct oral anticoagulants (DOACs) in reducing the risk of dementia in patients with AF.
Methods:
We conducted target trial emulation using data from the TriNetX research network. Patients with AF were allocated to 2 cohorts (2270 patients in each one), treated either with LAAO or with DOACs, and balanced with propensity score matching. The primary end points were composite dementia, vascular dementia, and Alzheimer disease. Secondary end points included mortality, ischemic stroke, intracranial hemorrhage, and major adverse cardiovascular events. Follow-up was conducted over 3 years.
Results:
At 3-year follow-up, the risk of composite dementia was lower in the LAAO group than in the DOAC group (hazard ratio 0.57; 95% confidence interval 0.38-0.85). Subgroup analyses demonstrated consistent results, favoring the LAAO group. No significant differences were observed in the incidence of secondary outcomes.
Conclusion:
This real-world study suggests that LAAO is associated with a lower risk of dementia in patients with AF compared with DOACs. Further prospective research with long-term follow-up is needed to validate our findings in the population with AF.
